Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Longboard Pharmaceuticals, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/23/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies • Enrolled 52 participants with Developmental and Epileptic Encephalopathies into the PACIFIC Study • Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related epilepsies, CDKL5 deficiency disorder, among others • PACIFIC topline results remain on track for around year-end 2023 LA JOLLA, Calif., August 23, 2023 – Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has completed enrollment of its Phase 1b/2a clinical trial, the PACIFIC Stu..." |
|
| 08/14/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/04/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/27/2023 |
SC 13D/A
| PFIZER INC reports a 17.3% stake in LONGBOARD PHARMACEUTICALS, INC. |
| 03/10/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in LONGBOARD PHARMACEUTICALS INC |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| HBM Healthcare Investments Ltd. reports a 10% stake in Longboard Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Longboard Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 11.1% stake in LONGBOARD PHARMACEUTICALS IN |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/07/2023 |
8-K
| Results of Operations and Financial Condition, Other Events Interactive Data |
| 02/03/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 10% stake in Longboard Pharmaceuticals, Inc. |
| 01/25/2023 |
SC 13G/A
| INTEGRATED CORE STRATEGIES LLC reports a 7.3% stake in LONGBOARD PHARMACEUTICALS, INC. |
| 12/05/2022 |
8-K
| Investor presentation |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/12/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/30/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 09/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|